GPCRs-Targeted Drug Discovery Summit Leaderboard
  • Friday, May 1, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Obesity & Weight Loss Drug Development Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 6

Author

Pharma Journalist 8769 posts 0 comments

Alloy, Biogen Partner on Next-Gen Antisense Therapies

Apr 8, 2026
Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. to advance the development of next-generation antisense therapeutics targeting multiple…
Read More...

Neurocrine to Acquire Soleno in $2.9 Billion Deal

Apr 8, 2026
Neurocrine Biosciences, Inc. has entered into a definitive agreement to acquire Soleno Therapeutics, Inc. in an all-cash transaction valued at approximately $2.9 billion, marking a…
Read More...

Apnimed Secures $150M to Advance Sleep Apnea Drug Launch

Apr 8, 2026
Apnimed, Inc. has secured a senior secured credit facility of up to $150 million from funds managed by HealthCare Royalty Partners, providing a major financial boost as the company…
Read More...

Akari Partners with WuXi XDC on Novel Cancer Therapy

Apr 7, 2026
Akari Therapeutics Plc has announced a strategic partnership with WuXi XDC to accelerate the development of its next-generation antibody-drug conjugate (ADC) technology, marking a…
Read More...

Lilly to Acquire Centessa in $6.3 Billion Deal

Apr 1, 2026
Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals in a transaction valued at approximately $6.3 billion upfront, with additional…
Read More...

Teva Advances Biosimilars With FDA Approval and Filings

Apr 1, 2026
Teva Pharmaceutical Industries has announced a series of significant milestones in its biosimilars portfolio, underscoring progress in its broader “Pivot to Growth” strategy and…
Read More...

Symeres, Ambagon Partner on Novel Cancer Drug Approach

Apr 1, 2026
Symeres has entered into a strategic collaboration with Ambagon Therapeutics to explore a promising new class of small molecules known as molecular glues for the treatment of colorectal…
Read More...

Biogen to Acquire Apellis in $5.6 Billion Deal

Apr 1, 2026
Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion, marking a significant step in Biogen’s strategy to…
Read More...

FDA Approves Higher-Dose Spinraza Regimen for SMA Patients

Apr 1, 2026
Biogen Inc. has announced that the U.S. Food and Drug Administration has approved a high-dose regimen of its therapy SPINRAZA for the treatment of spinal muscular atrophy (SMA), marking…
Read More...

In Vivo Cell Engineering Reaches an Inflection Point as the 5th In Vivo Cell Engineering & Gene…

Apr 1, 2026
The 5th In Vivo Cell Engineering & Gene Editing Summit returns to Boston this July, bringing together the scientific, translational, regulatory, and corporate leaders driving one of…
Read More...
Prev Next
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
GPCRs-Targeted Drug Discovery Summit
5th World ADC Summit South Korea
Extrahepatic Lipid-Based Nanoparticles Delivery Summit
World TPD & Induced Proximity Summit South Korea
Measuring Patient Engagement Summit
Investigative & Preclinical Toxicology Summit 2026
LEAP HR: Life Sciences West
Oligonucleotides for CNS Summit
R&D Procurement & Sourcing in Pharma Summit
In Vivo Cell Engineering & Gene Editing Summit
PFS & Injectable Drug Delivery West Coast
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
World Bispecific & T-Cell Engager Summit South Korea
TCR-Based Therapies Summit
PFS & Injectable Drug Devices East Coast
5th ADC Analytical Development Summit
Nasal Formulation & Delivery Summit
Peptide-Based Therapeutics Summit 2026
ALS Drug Development Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Gilead Completes $7.8 Billion Arcellx Acquisition Deal
  • EU Approves Rhapsido for Chronic Hives Treatment
  • Lilly to Acquire Ajax in $2.3 Billion Deal
  • Saphnelo Pen Approval Expands Lupus Treatment Access
  • BioMarin Completes $4.8 Billion Amicus Acquisition

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

Turning Biophysical Data into Confident Drug Discovery…

Targeted LNP Delivery Beyond the Liver: The Challenges…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.